Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.

ABSTRACT:

Background

The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening-detected lung tumors is currently unknown.

Methods

Targeted next-generation sequencing was performed on 94 LDCT screening-detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed.

Results

The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of pa

SUBMITTER: Verri C 

PROVIDER: S-EPMC6832691 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature